Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=375 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) — 9.574 months
Phase 3 N=702 Pediatric Open-Label Extension Study
Schizophrenia · Autism · Bipolar Depression
Primary: Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) — 214; 106; 252; 572 Participants
Phase 3 N=48 Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
Islet Transplantation in Diabetes Mellitus Type 1
Primary: Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent…
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
Phase 3 N=99 Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Acute Myocardial Infarction
Primary: Acute Phase Response (CRP Levels) — 60.03; 86.35; 213.75 mg x day/L (milligram x day/liter)
Phase 3 N=210 Rifaximin for Prevention of Travellers' Diarrhea
Diarrhea
Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants
Phase 3 N=122 A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event — 7; 6; 3; 5 Participants
Phase 3 N=398 Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.9; 13.5 Score on Scale — p=0.0438
Phase 3 N=404 Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.7; 11.3 Score on Scale — p=0.0048
Phase 3 N=820 Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Acne
Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -21.9; -13.9 lesion count — p=<0.001
Phase 3 N=673 Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 13.1; 12.0; 11.2 Score on scale — p=0.0830
Phase 3 N=30 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
Type II Diabetes Mellitus
Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl
Phase 3 N=109 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants